A Practical Guide to Writing Risk Management Plans (RMPs) (Online Course: March 19th, 2027)

Expert-led, practical EU RMP training covering current templates, risk minimisation tools, lifecycle updates and best practices for regulatory compliance


Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "A Practical Guide to Writing Risk Management Plans (RMPs) (Mar 19, 2027)" training has been added to ResearchAndMarkets.com's offering.

In the EU, all companies are required to provide Risk Management Plans (RMPs) for every new product, including both generic medicines and new chemical entities, and to maintain and update these plans throughout the entire lifecycle of a medicine.

This intensive one-day course delivers a clear, practical, and comprehensive overview of how to write, maintain, and update RMPs, equipping you with expert guidance and real-world insights to help you achieve and maintain full regulatory compliance with confidence.

You will gain practical, actionable advice on best practice for using EU templates and risk minimisation tools, enabling you to strengthen benefit-risk profiles and enhance regulatory submissions. Through expert-led discussion, you will build a robust understanding of how to apply regulatory expectations effectively in your daily work.

The course reflects the latest regulatory updates and new requirements, including amendments made to the previous template - ensuring the content is fully current, relevant, and immediately applicable.

CPD Hours: 6

Who Should Attend?

This course is ideal for professionals working in pharmacovigilance who are involved in writing RMPs, including medical directors and QPPVs responsible for approving these plans. It is also highly relevant for those working closely with pharmacovigilance, including professionals in:

  • Regulatory affairs
  • Clinical and pre-clinical
  • Sales and marketing
  • Legal
  • Commercial
  • Quality Assurance

Key Topics Covered:

  • An introduction to RMPs
  • Outline of EU RMPs
  • The EU templates and their completion - generic and innovator products
  • Completion of RMPs in other countries
  • The EU RMP and relationship with other documents
  • The RMP and Risk Minimisation Follow up
  • Overview of the sections of the EU RMP template
  • Final discussion session

Speaker

Graeme Ladds

Graeme Ladds, Director of PharSafer, has over 30 years' experience in the pharmaceutical industry. He began his career in 1989 at Ashbourne Pharmaceuticals as Head of Drug Safety & Medical Information, before going on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals.

He later founded his consultancy and specialist CRO, PharSafer Associates Ltd, where he has supported companies in establishing pharmacovigilance systems, conducting audits across Europe and the USA, developing SOPs, acting as a QP, and supporting regulatory inspections.

Since 1994, Graeme has also been involved in the monitoring of medical devices, including drug-device combinations, structural devices and electrical medical devices. His experience spans clinical trials and global device vigilance, alongside pharmacovigilance activities across both clinical development and post-marketing phases.

For more information about this training visit https://www.researchandmarkets.com/r/rve7xb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Kontaktdaten

GlobeNewswire